Furthermore, the elevated prominence of PSA as a prognostic predictor may be also biased by data generation and reporting, as it is routinely measured in prostate cancer follow-ups, while real-world clinical applications may be less prone to adapt novel markers into routine use. This evidence concerns the gene KLK3 and prostate carcinoma.